Business Wire

Replicor Announces Publication of Its REP 101 and REP 102 Studies Demonstrating the Therapeutic Effect of NAPs and the Achievement of Functional Control Off Treatment in Human Patients with Chronic Hepatitis B Infection


Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of clinical data from its REP 101 and REP 102 studies demonstrating the therapeutic effect of nucleic acid polymers (NAPs) in patients with HBeAg positive chronic HBV infection in the journal PLOS ONE (

The REP 101 study (NCT02646163) assessed the safety and efficacy of Replicor’s first clinical NAP candidate, REP 2055, as a weekly monotherapy in patients with HBeAg positive chronic HBV infection. The follow-on REP 102 study (NCT02646189), conducted in similar patients, used an improved NAP candidate (REP 2139) in an improved formulation with better administration tolerability (REP 2139-Ca) and included transition from monotherapy to brief (13-26 weeks) combination therapy with thymosin alpha 1 or pegylated interferon alpha 2a.

In both studies, NAP monotherapy was accompanied by 2 – 7 log reductions of serum HBsAg, 3 – 9 log reductions in serum HBV DNA, seroconversion of HBeAg and the appearance of serum anti-HBsAg antibodies. Self-resolving flares in liver transaminases in many patients (considered indirect evidence of antiviral immune activity in the liver) which peaked during the clearance of serum viremia were also observed. In the REP 102 study, 9 patients transitioned to combined treatment with immunotherapy during which 8 experienced HBsAg loss and all 9 experienced rapid and dramatic increases in serum anti-HBsAg antibody titers before withdrawal of therapy.

After REP 2055 treatment, 3 / 8 patients maintained control of infection for 1 year and two of these patients have still maintained control 5 years off-treatment. After combination therapy in the REP 102 study, 8 of 9 patients maintained control of infection after treatment which has persisted for more than 2 years in four of these patients.

Based on these initial studies, an optimized NAP-based combination therapy is currently being evaluated in HBeAg negative chronic HBV infection in the REP 401 protocol (NCT02565719), which has the potential to more easily achieve the functional control of chronic HBV infection with a finite course of treatment.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at

Contact information

For Replicor Inc.
Alexandra Peterson, 212-508-9709

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

JustPremium Launches Rich Video Product Suite19.3.2018 08:00Pressemelding

Programmatic rich media and video ad marketplace, JustPremium, has today announced the launch of a new product suite, Rich Video. The new offering allows clients to build multiple rich video ad units with a single click using the advertisers existing assets. Using Rich Video allows advertisers to create an engaging advert, leading to higher engagement and interaction rates. Ultimately these formats help create a better user experience and a higher return on investment. JustPremium launches this product at a time when quality video inventory has never been more in demand, and brand-safe video inventory that advertisers require has never been in shorter supply. Rich Video allows publishers to build multiple creative ad units in minutes, enabling them to test different options and optimise their message to give the best performance. By utilising the assets that have already been created for Facebook, Adwords and YouTube, this process allows advertisers to supercharge their existing conten

GovSat-1 Satellite Goes Operational19.3.2018 07:40Pressemelding

GovSat-1 enters operational service today, to provide secure communications to governmental and institutional users. GovSat-1 is the first satellite of GovSat, a public private partnership between the Government of Luxembourg and the world-leading satellite operator SES. The satellite was launched into space on 31 January on board a flight-proven SpaceX Falcon 9 rocket from Cape Canaveral Air Force Station, and has since undergone extensive testing. This press release features multimedia. View the full release here: GovSat-1 launch. (Photo: SpaceX) The multi-mission satellite is operated by GovSat from the Secure Mission Operations Centre in Luxembourg. The highly flexible and resilient GovSat-1 payload uses dedicated frequencies in X-band and military Ka-band. It enables an array of applications such as connectivity for theatres of operation, interconnection of institutional or defence sites, border control, Intelligence, Surve

Digi Communications N.V.: Announcement on the Convocation Date for the Company’s GSM Approving the 2017 Annual Report19.3.2018 07:34Pressemelding

The Company would like to inform its investors and the market that the Board of Directors anticipates that on Wednesday, 21 March 2018, it will convene the general shareholders meeting (the “GSM”) called to approve, among others, the 2017 Annual Report. On the same date, the Company will make public, among others, its 2017 Annual Report and the auditor’s report. In accordance with the provisions of the articles of association of the Company, the GSM is scheduled to take place on 2 May 2018. Therefore, we would like to inform you with respect to the update to the Company’s Financial Reporting Calendar for 2018, which is available on Digi’s website. For details, please access the Digi’s website: (Investor Relations Section). About Digi Communications NV Digi is the parent holding company of RCS & RDS, a leading provider of pay TV and telecommunications services in Romania and Hungary. In addition, RCS & RDS provides mobile services as an MVNO to the large Roman

Dai Nippon Printing Chooses Gemalto’s Biometric Facial Recognition Solution to Facilitate Mobile Banking Access in Japan19.3.2018 06:00Pressemelding

Gemalto, the world leader in digital security, today announced that it has been selected by Dai Nippon Printing (DNP), a financial solutions provider in Japan, to make mobile banking transactions easier to use. Leveraging Gemalto’s facial biometric authentication solution - Mobile Protector- DNP has started to offer facial recognition to secure access to its mobile banking apps. This enables banking customers to easily and quickly log on to mobile banking services upon successful facial authentication, providing a more convenient user experience. This press release features multimedia. View the full release here: Facial recognition for mobile banking authentication. (Photo: Gemalto) Gemalto’s 2017 eBanking Trends research found that 68 percent of banks plan to implement facial recognition over the next five years. 80 percent of surveyed consumers perceived biometrics to be more secure than the traditional username and password co

Gemalto Helps European Banks Build Business Opportunities from PSD219.3.2018 06:00Pressemelding

Gemalto, the world leader in digital security, believes that the implementation of PSD2 (Payment Services Directive 2) offers European banks a unique opportunity to deliver digital innovation, robust protection and seamless user experience that will be critical in a new era of open markets. The Regulatory Technical Standards (RTS) have just been published in the EU Official Journal, and detail the responsibilities and obligations of all banking and payment stakeholders concerning access to account, customer data protection, user convenience, and payment security. Gemalto believes that long term success will be built around solutions tailored to individual requirements, whilst drawing on products and services already proven to deliver the core principles of PSD2. This press release features multimedia. View the full release here: Solutions to help financial institutions for implementation of PSD2. Credit: istockphoto Adoption of t

ExThera Medical Announces Creation of European Subsidiary19.3.2018 05:23Pressemelding

ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary. Carla brings more than 30 years of experience in clinical research and the commercialization of new medical devices in the European market to ExThera Medical, where she will oversee the strategic direction for ExThera’s European operations. “The establishment of our European subsidiary is an exciting milestone as we prepare for commercialization,” said Robert Ward, President and CEO of ExThera Medical. “Carla has a distinguished track record in medical device development and commercialization, including overseeing clinical research, regulatory affairs, quality assurance, and operations. As CEO of her company, Meditech, she successfully supported the rapid clinical adoption of many new medical devices. Carla’s strategic leadership w